Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7069837 | 0.92 | ALDH1A1 (0.47) | ALDH1A1TP53THRBMAPTHTT | |
| SCHEMBL7068309 | 0.85 | NAMPT (0.50) | ALDH1A1TP53THRBTSHRMAPT | |
| SCHEMBL7074425 | 0.83 | ALDH1A1 (0.46) | ALDH1A1THRBTSHRMAPTHTT | |
| SCHEMBL7069769 | 0.83 | POLB (0.50) | ALDH1A1HTTPOLBNAMPTSMN1; SMN2 | |
| SCHEMBL7070258 | 0.83 | PLAU (0.53) | ALDH1A1THRBTSHRMAPK10MAPT | |
| SCHEMBL7071815 | 0.83 | ALDH1A1 (0.44) | ALDH1A1THRBMAPTHTTPOLB | |
| SCHEMBL7400914 | 0.82 | HDAC6 (0.49) | ALDH1A1MAPTHTTPOLBNAMPT | |
| SCHEMBL7075759 | 0.81 | FLT3 (0.49) | ALDH1A1HTTPOLB | |
| SCHEMBL7075818 | 0.81 | NPC1 (0.55) | ALDH1A1TP53THRBTSHRMAPT | |
| SCHEMBL7073255 | 0.81 | KMT2A (0.53) | ALDH1A1MAPTLMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6562854-B2 | Antiinflammatory agents; respiratory system disorders | AXYS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | Celera Corporation | 2001-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | CMA1, CPA3, TPSG1 | ALDH1A1 1860/4885TP53 3162/4885RIPK1 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.